» Articles » PMID: 28679689

Two Different, Mutually Exclusively Distributed, Mutations in Ovarian and Peritoneal Tumor Tissues of a Serous Ovarian Cancer Patient: Indicative for Tumor Origin?

Overview
Specialty Genetics
Date 2017 Jul 7
PMID 28679689
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

High-grade serous ovarian cancer (HGSOC) is characterized by a mutation rate of up to 96.7% and associated with a more aggressive tumor biology. The origin of HGSOC is thought to arise either from fallopian tube secretory cells or the ovarian surface epithelium/inclusion cysts, the former with more evidence. Peritoneal tumor spread is heterogeneous, either excessive in the peritoneum (with miliary appearance) or more confined to the ovaries with only few (bigger and exophytically growing) peritoneal implants. Using RNA sequencing and DNA digital droplet polymerase chain reaction (PCR), we identified two different functional mutations in one HGSOC patient: one exclusively in the ovarian tumor mass and the other exclusively in ascites tumor cells, peritoneal tumor masses, and a lymph node metastasis. In blood, both mutations could be detected, the one from the peritoneal tumors with much higher frequency, presumably because of the higher tumor load. We conclude that this mutually exclusive distribution of two different mutations in different tumor tissues indicates the development of two independent carcinomas in the peritoneal cavity, probably one originating from a precancerous lesion in the fallopian tube and the other from the ovaries. In addition, in the patient's ascites CD45 and EpCAM, double-positive cells were found-proliferating but testing negative for the above-mentioned mutations. This mutually exclusive distribution of two mutations is probably further evidence that HGSOC can originate either from the fallopian tube or (more seldom) the ovaries, the former more prone for excessive peritoneal tumor spread.

Citing Articles

Application of single cell sequencing technology in ovarian cancer research (review).

Yuan Q, Lv N, Chen Q, Shen S, Wang Y, Tong J Funct Integr Genomics. 2024; 24(5):144.

PMID: 39196391 PMC: 11358195. DOI: 10.1007/s10142-024-01432-w.


Ninjurin 2, a Cell Adhesion Molecule and a Target of p53, Modulates Wild-Type p53 in Growth Suppression and Mutant p53 in Growth Promotion.

Zhang J, Kong X, Yang H, Mohibi S, Lucchesi C, Zhang W Cancers (Basel). 2024; 16(1).

PMID: 38201656 PMC: 10778559. DOI: 10.3390/cancers16010229.


Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art.

Kaigorodova E, Kozik A, Zavaruev I, Grishchenko M Biochemistry (Mosc). 2022; 87(4):380-390.

PMID: 35527376 PMC: 8993035. DOI: 10.1134/S0006297922040071.


A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types.

Pils D, Steindl E, Bachmayr-Heyda A, Dekan S, Aust S Cancers (Basel). 2020; 12(8).

PMID: 32806596 PMC: 7464642. DOI: 10.3390/cancers12082257.


NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer-An Integrative Multi-Omics Approach.

Bekos C, Muqaku B, Dekan S, Horvat R, Polterauer S, Gerner C Cancers (Basel). 2019; 11(5).

PMID: 31137558 PMC: 6562934. DOI: 10.3390/cancers11050698.


References
1.
. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

2.
Ahmed A, Etemadmoghadam D, Temple J, Lynch A, Riad M, Sharma R . Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010; 221(1):49-56. PMC: 3262968. DOI: 10.1002/path.2696. View

3.
Sliutz G, Schmidt W, Tempfer C, SPEISER P, Gitsch G, Eder S . Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis. Gynecol Oncol. 1997; 64(1):93-8. DOI: 10.1006/gyno.1996.4535. View

4.
Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D . COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2010; 39(Database issue):D945-50. PMC: 3013785. DOI: 10.1093/nar/gkq929. View

5.
Dearth L, Qian H, Wang T, Baroni T, Zeng J, Chen S . Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. 2006; 28(2):289-98. DOI: 10.1093/carcin/bgl132. View